Preparation, characterization, and in vitro/vivo evaluation of polymer-assisting formulation of atorvastatin calcium based on solid dispersion technique

Due to low solubility and bioavailability, atorvastatin calcium is confronted with challenge in conceiving appropriate formulation. Solid dispersion of atorvastatin calcium was prepared through the solvent evaporation method, with Poloxamer 188 as hydrophilic carriers. This formulation was then characterized by scanning electron microscopy, differential scanning calorimetry, powder X-ray diffraction and fourier transform infrared spectroscopy. Moreover, all these studies suggested the conversion of crystalline atorvastatin calcium. In addition, the drug solubility studies as well as dissolution rates compared with bulk drug and market tablets Lipitor were also examined. Furthermore, the study investigated the pharmacokinetics after oral administration of Lipitor and solid dispersion. And the AUC 0–8 h and C max increased after taking ATC-P188 solid dispersion orally compared with that of Lipitor. All these could be demonstrated that ATC-P188 solid dispersions would be prospective means for enhancing higher oral bioavailability of ATC.

Carobomer Based Controlled Release Designs of Atorvastatin Calcium Tablets Evaluated Using Quality by Design (QbD) Approach

The study carried out here was focused on developing conventional monolithic controlled release matrix tablet of Atorvastatin calcium using carbomer as release controlling polymer. This system ensures the drug release at the alkaline pH region where the drug has got maximum solubility. Further the study was concentrated on comparing the impact of gelling agent polyvinyl pyrrolidone on drug release. Quality by design tools were considered during formulation development and the polymer concentrations were optimized adopting the statistical tool, design of experiments (DoE). The optimized formulation of present study exhibited desired controlled drug release characteristics in the alkaline pH conditions and at acidic environment the drug dissolution was minimal as intended.

Effects of Atorvastatin calcium combined with Aspirin on serum levels of Hcy, NSE, UA, hs-CRP and inflammatory factors of patients with cerebral infarction

Objective:To study the effects of Atorvastatin calcium combined with Aspirin on serum levels of homocysteine (Hcy), neuron-specific enolase (NSE), uric acid (UA), high sensitity C-reactive protein (hs-CRP) and inflammatory factors of patients with cerebral infarction. Methods:100 cases of patients with cerebral infarction from March 2014 to May 2016 were treated in the Department of Neurology of our hospital and affiliated to Huazhong University of Science and Technology of traditional Chinese medicine and Western Medicine. The subjects were divided into the control group (n=50) and the treatment group (n=50) randomly. The control group was treated with Aspirin, the treatment group were treated with Atorvastatin calcium combined with Aspirin. The two groups were treated for 28 d. The serum levels of Hcy, NSE, UA, hs-CRP, interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-α(TNF-α) of the two groups before and after treatment were compared. Results:There were no significantly differences of the serum levels of the Hcy, NSE, UA and hs-CRP of the two groups before treatment (P>0.05). After treatment, the serum levels of the Hcy, NSE, UA and hs-CRP of the two groups were significantly lower than before treatment, and that of the treatment group were significantly lower than the control group (P<0.05). There were no significantly differences of the serum levels of the IL-6, IL-8 and TNF-αof the two groups before treatment (P>0.05). After treatment, the serum levels of the IL-6, IL-8 and TNF-αof the two groups were significantly lower than before treatment, and that of the treatment group were significantly lower than the control group (P<0.05). Conclusions:Atorvastatin calcium combined with Aspirin can significantly reduce the serum levels of Hcy, NSE, UA, hs-CRP, IL-6, IL-8 and TNF-αof the patients with cerebral infarction.

The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo

A biodegradable poly(lactic-co-glycolic acid) loading atorvastatin calcium(AC) nanoparticles(AC-PLGA-NPs) were prepared by probe ultrasonication and evaporation method aiming at improving the oral bioavailability of AC. The effects of experimental parameters, including stabilizer species, stabilizer concentration and pH of aqueous phase, on particle size were also evaluated. The resultant nanoparticles were in spherical shape with an average diameter of 174.7 nm and a narrow particle size distribution. And the drug loading and encapsulation efficiency were about 8% and 71%, respectively. The particle size and polydispersion were almost unchanged in 10 days. The release curves of AC-PLGA-NPs in vitro displaying sustained release characteristics indicated that its release mechanisms were matrix erosion and diffusion. The pharmacokinetic study in vivo revealed that the Cmax and AUC0-∞ of AC-PLGA-NPs in rats were nearly 3.7-fold and 4.7-fold higher than that of pure atorvastatin calcium suspension. Our results demonstrated that the delivery of AC-PLGANPs could be a promising approach for the oral delivery of AC for enhanced bioavailability.

Effect of atorvastatin calcium on the carotid atherosclerotic plaque and cerebral blood flow indicators in patients with TIA

Objective:To explore the effect of atorvastatin calcium on the carotid atherosclerotic plaque, serum lipid level, and cerebral hemodynamic indicators in patients with transient ischemic attack (TIA).Methods:A total of 80 patients with TIA and carotid atherosclerotic plaque who were admitted in our hospital and confirmed by the ultrasound were included in the study and randomized into the treatment group and the control group (n = 40). The patients in the two groups were given TIA routine treatments and aspirin. On this basis, the patients in the treatment group were given atorvastatin calcium. The carotid ultrasound before treatment and 6 months after treatment in the two groups was performed to compare the atherosclerotic plaque area and IMT. The serum lipid level and cerebral hemodynamic parameters were detected. Results:IMT and carotid plaque area after treatment in the treatment group were significantly reduced when compared with before treatment (P<0.05). IMT and carotid plaque area after treatment in the treatment group were significantly lower than those in the control group (P<0.05). The comparison of TC, TG, LDL, and HDL levels before treatment between the two groups was not statistically significant (P>0.05). TC, TG, and LDL levels after treatment were significantly reduced when compared with before treatment (P<0.05), while HDL level was significantly elevated when compared with before treatment (P<0.05). TC, TG, and LDL levels after treatment in the treatment group were significantly lower than those in the control group (P<0.05), while HDL level was significantly higher than that in the control group (P<0.05). The average blood velocity and average blood flow volume of cerebral circulation after treatment in the treatment group were significantly higher than those in the control group (P<0.05), while the cerebrovascular characteristic resistance and peripheral resistance were significantly lower than those in the control group (P<0.05).Conclusions:Atorvastatin calcium in the treatment of TIA can significantly reduce the serum lipid level, alleviate or stabilize the carotid atherosclerotic plaque, and improve the cerebral hemodynamic indicators, with a significant efficacy.

阿托伐他汀预处理对PCI治疗的ACS患者血脂及cTnI、CKMB水平的影响

目的探讨阿托伐他汀预处理对经皮冠状动脉介入治疗(PCI)患者血清脂质及心肌肌钙蛋白I(cTnI)和肌酸激酶同工酶(CK-MB)水平的影响。方法选取河北医科大学第一医院2016年6月-2018年6月收治的符合纳入标准的90例急性冠脉综合征患者,采用随机数字表法分为观察组(n=45)及对照组(n=45)。两组患者术前均常规给予口服阿司匹林100 mg、氯吡格雷300 mg及静脉输注普通肝素(80 IU/kg)等药物治疗。观察组术前给予阿托伐他汀40 mg(立普妥20 mg/片,辉瑞)口服,对照组术前给予安慰剂100 mg(维生素C片剂)口服。两组术后口服阿托伐他汀(20 mg/d),疗程3个月。患者出院后随访1年。结果两组术前血清总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白(LDL-C)水平差异无统计学意义(P<0.05)。两组患者术后7 d血脂水平较术前及术后第1天明显下降(P<0.05),且观察组显著低于对照组(P<0.05)。两组患者术前超敏C反应蛋白(hs-CRP)水平差异无统计学意义(P=0.898),两组患者术后1 d hs-CRP水平较术前均显著增高,但组间差异无统计学意义(P=0.135),术后7 d hs-CRP水平明显低于术后1 d(P=0.000),观察组明显低于对照组(P=0.000)。两组术前cTnI和CK-MB水平差异无统计学意义(P<0.05),术后1 d cTnI和CK-MB水平明显高于术前(P=0.000),但两组间差异无统计学意义(P<0.05),术后7 d cTnI和CK-MB水平较术后1 d显著下降(P=0.000),且观察组显著低于对照组(P=0.000)。观察组总不良心血管事件发生率低于对照组,差异有统计学意义(P=0.01)。结论阿托伐他汀预处理可有效降低患者的血脂和cTnI、CK-MB水平,降低不良心血管事件发生率。

替罗非班和瑞舒伐他汀对NSTE-ACS患者PCI术后肌酸激酶同工酶和肌钙蛋白及肾功能的影响

目的探讨替罗非班和瑞舒伐他汀对非ST段抬高型急性冠状动脉综合征(non ST elevation acute coronary syndromes,NSTE-ACS)患者经皮冠状动脉介入(PCI)术后对肌酸激酶同工酶和肌钙蛋白及肾功能的影响。方法将62例NSTE-ACS患者随机分成强化组和对照组,强化组患者服用瑞舒伐他丁负荷剂量30mg/d,并先将盐酸替罗非班10μg/kg静脉推注,后按0.15μg/(kg min)速度静脉泵入,持续24～36h。对照组仅服用瑞舒伐他丁常规剂量10mg/d,预处理3～5d后行PCI术,术后观察两组的有效率情况,检测肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTn1)和肌酐清除率(CrCI),进行分析比较。结果术后2周,强化组的总有效为90.32%,显著高于对照组的70.97%,P<0.05;术后24h,强化组的肌酸激酶同工酶(CK-MB)为(0.30±0.04)μg/L,肌钙蛋白(cTnI)为(0.25±0.1)μg/L,均显著低于对照组的(0.39±0.12)μg/L和(0.48±9.21)μg/L,肌酐清除率(CrCI)强化组为(54.92±6.35)mL/min,显著高于对照组(36.21±4.66)mL/min,P<0.05。结论对NSTE-ACS患者PCI术采用替罗非班和瑞舒伐他汀预处理减少了术后心肌损伤,增强了肾功能,且具有良好的临床疗效。

行择期经皮冠状动脉介入治疗术的ACS患者TLR4表达水平及阿托伐他汀对其的影响

目的 分析急性冠状动脉综合征（Acute Coronary Syndrome,ACS）患者行择期经皮冠状动脉介入治疗（PCI）术后外周血单核细胞Toll样受体4（TLR4）的表达水平与ACS发生和冠脉病变程度的相关性,观察增加阿托伐他汀剂量治疗对TLR4表达的影响。方法 选取台州恩泽医疗中心（集团）浙江省台州医院心血管内科2014年5月~2016年5月收治的100例行择期PCI术的ACS患者。将其随机分为对照组和实验组,对照组入院后予以阿托伐他汀20 mg/d治疗,PCI术后持续,1月后仍维持20 mg/d剂量。实验组入院后予以阿托伐他汀40 mg/d治疗,PCI术后,1月后减量至20 mg/d。采用流式细胞检测仪对患者入院后、1疗程治疗后外周血单核细胞TLR4表达水平进行检测,并采用Gensini评分系统对患者冠脉病变程度进行评分。同时选择体检健康者50例作为正常组进行对比。结果 相较于体检正常组,ACS患者外周血单核细胞TLR4水平明显升高,而且不稳定型心绞痛患者升高水平远低于急性心肌梗死患者,3支病变患者明显高于1、2支病变患者,三者比较差异具有统计学意义（P〈0.01）;根据多元逐步线性回归和其他分析结果显示ACS类型、冠状动脉病变支数、冠状动脉狭窄积分与外周血单核细胞TLR4表达水平呈正相关,对其影响最大（P〈0.05）;行阿托伐他汀治疗1月后2组患者外周血单核细胞TLR4表达水平、低密度脂蛋白胆固醇、总胆固醇水平明显降低,高密度脂蛋白胆固醇水平明显升高,差异均具有统计学意义（P〈0.01）;同正常组相比,实验组外周血单核细胞Toll样受体4表达水平、总胆固醇、低密度脂蛋白胆固醇降低程度高于正常组,高密度脂蛋白胆固醇升高幅度较为明显,组间比较差异均具有统计学意义（P〈0.01）。结论 ACS发生及病变程度与患者外周血单核细胞Toll样受体4表达水平增加具有一定相关性,增加阿托伐他汀使用剂量能够显著降低ACS患者PCI术后外周血单核细胞Toll4样受体表达水平。

硬脂酸钙和硬脂酸锌对PVC/AC配方体系发泡温度的影响

在软质PVC基体材料中,分别测定了硬脂酸钙和硬脂酸锌两种发泡促进剂与主发泡剂AC在不同配比下的发泡温度。结果表明,随促进剂/AC质量比的增加,AC分解温度可以在一定程度上降低;硬脂酸钙/AC的质量比从0∶1增加到4∶1时,可以使AC的发泡温度从182℃降至168℃;硬脂酸锌/AC的质量比从0∶1增加到3∶1时,可以使AC的发泡温度从185℃降至166℃;某些配比下温度的变化不明显,有时有波动甚至突变。

ACL的构建及其对结直肠癌HCT116细胞增殖和迁移的作用

目的制备阿托伐他汀钙脂质体(ACL),探究其对结直肠癌HCT116细胞增殖、迁移的影响。方法采用乳化-溶剂挥发法制备ACL并进行相关参数的测定。以香豆素6为荧光探针探究HCT116细胞摄取的变化;MTT实验和细胞平板克隆实验检测ACL和阿托伐他汀钙(AC)对HCT116细胞增殖的影响;Transwell实验检测ACL和AC对HCT116细胞迁移的影响。结果成功制备ACL,其平均粒径为(87.24±0.485)nm,分散系数为0.240~0.250,Zeta电位为(-12.19±3.642)mV。脂质体形态似球形或圆形结构,外观完整,且大小均匀。脂质体组细胞内荧光强度显著增强,细胞摄取增加。AC和ACL作用后,细胞增殖率和克隆形成率显著降低,迁移细胞数减少,且ACL的抑制作用均显著强于AC。结论ACL可以显著增加HCT116细胞的摄取,增强AC对HCT116细胞的抑制作用。

Clinical pharmaceutical analysis of combined therapy with amlodipine benzenesulfonate and atorvastatin calcium for elderly patients with hypertension and dyslipidemia

Background Hypertension combined with dyslipidemia is the main cause of cerebrovascular and cardiovascular accidents in elderly patients,and actively controlling blood pressure and lipid levels is the best way to reduce the risk of cardiovascular accidents and death.This study focused on the clinical pharmaceutical analysis of combined therapy with amlodipine benzenesulfonate and atorvastatin calcium for elderly patients with hypertension and dyslipidemia.Methods A total of 292 elderly patients with hypertension and dyslipidemia from August 2022 to February 2023 were selected and grouped according to random number table method,and evenly assigned to control group(n=146)and observation group(n=146).Control group was treated with amlodipine besylate,and observation group was treated with combined therapy with amlodipine benzenesulfonate and atorvastatin calcium.The effects and adverse reactions of the two groups were compared,and the changes of blood pressure and lipid indexes before and after treatment were also compared.Results The total effective rate of observation group was higher than that of control group,the difference was significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).No significant differences were found in systolic blood pressure,diastolic blood pressure,total cholesterol and triglyceride between the two groups before treatment(P>0.05).While after treatment,the level of systolic blood pressure,diastolic blood pressure,total cholesterol and triglyceride in the observation group were lower than those in the control group(P<0.05).Conclusions The combination therapy with amlodipine benzenesulfonate and atorvastatin calcium is effective and safe,improving blood pressure and lipid levels in patients with hypertension and dyslipidemia,and can be widely applied to elderly patients with hypertension and dyslipidemia.[S Chin J Cardiol 2024;25(1):38-43].

阿托伐他汀短期治疗对ACS初期MMPS-9、TNF-α、vWF的影响

目的:观察急性冠脉综合征患者初期给予不同剂量阿托伐他汀短期治疗对基质金属蛋白酶-9(MMPS-9)、肿瘤坏死因子α(TNF-)α、假性血友病因子(vWF)的影响,探讨急性冠脉综合征初期患者他汀类药物的非调脂作用和剂量效应。方法:60例急性冠脉综合征患者随机分为阿托伐他汀40mg治疗组、阿托伐他汀10mg治疗组(各30例),分别治疗7天,测定治疗前后血清MMPS-9、TNF-α、vWF及血脂、肝、肾功能等常规生化指标。结果:①2组病例治疗前后血脂各项指标变化差异均无显著性(P>0.05);②阿托伐他汀40 mg治疗组和10 mg治疗组治疗后血清MMPS-9、TNF-α、vWF水平均明显下降,与治疗前比较差异均有显著性(P<0.05);③阿托伐他汀40 mg治疗组治疗后血清MMPS-9、TNF-α、vWF水平与阿托伐他汀10 mg治疗组比较差异有显著性(P<0.05)。结论:急性冠脉综合征患者初期给予阿托伐他汀短期治疗,可明显降低MMPS-9、TNF-α、vWF的水平,且强化治疗后更明显,这对稳定冠脉粥样斑块有积极的意义。

普罗布考联合阿托伐他汀钙治疗急性脑梗死的疗效

目的评估普罗布考与阿托伐他汀钙联合治疗急性脑梗死(acute cerebral infarction,ACI)的疗效,以提供ACI的治疗参考方案。方法回顾性收集2018年1月—2023年9月在重庆市急救医疗中心就诊,发病24 h内住院的ACI患者资料。纳入患者需满足:接受了阿托伐他汀钙(20 mg,每晚1次)单药或联用普罗布考(0.5 mg,每日2次)调节血脂治疗,且治疗周期为3个月以上。根据是否联用普罗布考分为联合治疗组和对照组,比较两组治疗后神经功能(使用NIHSS评估)、神经功能结局(使用mRS评估)、生活能力(使用Barthel指数评估)以及血脂水平的差异。结果研究共入组102例患者,其中联合治疗组56例,对照组46例。两组的基线资料差异无统计学意义。治疗后14 d两组的NIHSS评分和血脂水平、治疗3个月后的血脂水平均较本组治疗前显著改善(均P<0.001)。治疗14 d时,联合治疗组的NIHSS评分(P=0.031)、TC(P=0.005)和LDL-C(P=0.044)水平低于对照组,Barthel指数(P=0.004)高于对照组,差异有统计学意义。治疗3个月时,联合治疗组的mRS评分(P<0.001)、TC(P<0.001)、TG(P=0.002)和LDL-C(P<0.001)水平低于对照组,Barthel指数高于对照组(P<0.001),差异有统计学意义。随访3个月期间联合治疗组的脑梗死复发率为0,对照组为2.17%,但差异无统计学意义(P=0.268)。结论普罗布考联合阿托伐他汀钙治疗ACI急性期患者,相较于单独使用阿托伐他汀钙,具有更佳的临床疗效,能有效降低血脂水平并改善患者的神经功能及生活能力。

非布司他联合阿托伐他汀钙治疗高脂血症合并高尿酸血症患者的效果

目的:观察非布司他联合阿托伐他汀钙治疗高脂血症合并高尿酸血症患者的效果。方法:选取2020年2月至2023年3月该院收治的120例高脂血症合并高尿酸血症患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各60例。对照组予以阿托伐他汀钙治疗,观察组在对照组基础上联合非布司他治疗。比较两组临床疗效、治疗前后血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]水平、血尿酸水平、血管内皮功能指标[可溶性细胞间黏附分子-1(sICAM-1)、内皮素-1(ET-1)]水平和不良反应发生率。结果:观察组治疗总有效率为93.33%(56/60),高于对照组的80.00%(48/60),差异有统计学意义(P<0.05);治疗后,观察组TG、TC、LDL-C、血尿酸水平均低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);观察组sICAM-1、ET-1水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:非布司他联合阿托伐他汀钙治疗高脂血症合并高尿酸血症患者可提高治疗总有效率,改善血脂指标水平,降低血尿酸和血管内皮功能指标水平,效果优于单纯阿托伐他汀钙治疗。

参麦注射液治疗冠心病慢性心力衰竭

目的探究参麦注射液治疗冠心病慢性心力衰竭(CHD-CHF)临床疗效及对左心功能、血清因子、血清凝血指标的影响。方法选择冠心病慢性心力衰竭患者118例,随机数表法分为观察组与对照组,各59例。对照组予阿托伐他汀钙片治疗,观察组在对照组基础上联合参麦注射液治疗,2组均治疗1个月。比较2组临床疗效,治疗前后左心功能、血清因子、血清凝血指标水平变化,治疗期间不良反应发生情况。结果观察组临床疗效总有效率(91.53%,54/59)高于对照组(72.88%,43/59)(P<0.05)。治疗后,2组血清脑钠肽(BNP)、神经肽Y(NPY)、肌酸激酶同工酶-MB(CK-MB)、粒膜蛋白140(GMP-140)、血管性血友病因子(vWF)、纤维蛋白原(FIB)、D-二聚体(D-D)水平及左心室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)水平均较治疗前下降,且观察组低于对照组(P<0.05);2组左心室射血分数(LVEF)水平均较治疗前升高,且观察组高于对照组(P<0.05)。观察组不良反应发生率低于对照组(P<0.05)。结论参麦注射液联合阿托伐他汀钙片治疗冠心病慢性心力衰竭患者,可降低血清BNP、NPY、CK-MB水平,调节凝血指标,改善左心功能,疗效确切且安全性高。

阿托伐他汀钙下调肌微管素相关蛋白3诱导自噬抑制结肠癌HCT116细胞增殖迁移

目的:探讨阿托伐他汀钙(ATO)诱导自噬抑制结直肠癌(CRC)HCT116细胞增殖与迁移的机制。方法:采用免疫组化检测结直肠癌组织及癌旁组织中肌微管素相关蛋白3(MTMR3)及P62的表达,用0、12.5、25、50、100μmol/L浓度ATO处理结直肠癌HCT116细胞系24 h,采用MTT法检测HCT116细胞活力,使用12.5、25、37.5μmol/L ATO处理HCT116细胞后,进行克隆集落形成实验及细胞划痕实验,并用Western blot法检测其MTMR3及自噬相关蛋白LC3和P62蛋白的表达。ATO联合si-MTMR3、ATO联合自噬抑制剂氯喹及单独氯喹处理结肠癌细胞HCT116,检测HCT116细胞活力、集落形成及迁移能力,并使用Western blot法检测MTMR3、LC3和P62蛋白表达。结果:MTMR3和P62在CRC组织中高表达,经ATO处理的HCT116细胞,药物浓度越高,细胞活力、集落形成和迁移能力越低,其MTMR3及P62蛋白表达亦明显下降,自噬相关蛋白LC3II/I比值逐渐升高,自噬抑制剂氯喹可逆转ATO对HCT116细胞的抑制作用,si-MTMR3与ATO对HCT116细胞有协同抑制作用,并且si-MTMR3可诱导自噬的发生。结论:ATO能抑制结肠癌HCT116细胞的增殖及迁移,其机制可能与通过抑制MTMR3的表达、诱导细胞自噬有关。

阿托伐他汀钙片+依达拉奉治疗ACI并CMBs患者的效果及对氧化应激状态的影响

目的探讨急性脑梗死(ACI)并脑微出血(CMBs)患者采用阿托伐他汀+依达拉奉联合治疗对临床疗效、氧化应激状态的影响。方法选取沁阳市中医院2019年1月至2020年1月收治的ACI并CMBs患者130例,根据随机数字表法将患者分为对照组(N=65)与观察组(N=65)。对照组给予阿托伐他汀钙片治疗,观察组在对照组基础上加用依达拉奉治疗,对两组患者临床疗效、治疗前后神经缺损功能及氧化应激指标变化进行比较。结果两组治疗后美国国立卫生院神经功能缺损评分(NIHSS)较治疗前下降,差异有统计学意义(P<0.05),与对照组相比,观察组评分更低,差异有统计学意义(P<0.05);与对照组(73.85%)相比,观察组治疗有效率(93.82%)更高,差异有统计学意义(P<0.05);两组治疗后超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平较治疗前提高,差异有统计学意义(P<0.05),髓过氧化物酶(MPO)水平下降,差异有统计学意义(P<0.05),与对照组相比,观察组治疗后SOD、GSH-Px水平更高(P<0.05),MPO水平更低,差异有统计学意义(P<0.05)。结论ACI并CMBs患者采用阿托伐他汀钙片+依达拉奉治疗效果显著,可提高神经功能及改善氧化应激指标。

依洛尤单抗联合阿托伐他汀钙治疗冠心病合并高血脂的效果及安全性

目的探讨依洛尤单抗联合阿托伐他汀钙治疗CHD合并高血脂的效果及安全性。方法102例CHD合并高血脂患者随机分为对照组(阿托伐他汀钙)和观察组(依洛尤单抗+阿托伐他汀钙),比较两组的疗效和不良反应。结果治疗后,观察组的TG、TC、LDL-C、ApoB水平均低于对照组,LDL-C达标率高于对照组(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论依洛尤单抗联合阿托伐他汀钙治疗CHD合并高血脂可下调患者的血脂水平,安全性尚可。

阿托伐他汀钙片联合布地奈德福莫特罗吸入粉雾剂治疗慢性阻塞性肺疾病的临床疗效及对患者血气分析指标的影响

目的:探讨阿托伐他汀钙片联合布地奈德福莫特罗吸入粉雾剂治疗慢性阻塞性肺疾病(COPD)患者的临床疗效,及对患者血气分析指标的影响。方法:选取2021年12月~2023年12月期间某院收治的120例COPD患者作为研究对象,按照随机数字表法分为对照组和观察组,每组60例。对照组患者给予布地奈德福莫特罗吸入粉雾剂(Ⅱ)治疗,观察组在对照组治疗基础上加用阿托伐他汀钙片,两组均连续治疗4周。比较两组患者临床疗效、肺功能[用力肺活量(FVC)、呼气流量峰值(PEF)和第1秒用力呼气容积/用力肺活量(FEV1/FVC)]、血气分析指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))和血氧饱和度(SO_(2))]、辅助性T细胞1/辅助性T细胞2(Th1/Th2)、辅助性T细胞17/调节性T细胞(Th17/Treg)及不良反应发生情况。结果:治疗后,观察组患者治疗总有效率(93.33%)高于对照组(75.00%,P<0.05)。两组患者FVC、PEF及FEV1/FVC均升高(P<0.05),且观察组高于对照组(P<0.05);两组患者PaO_(2)、SO_(2)均升高(P<0.05),且观察组高于对照组(P<0.05);两组患者PaCO_(2)均降低(P<0.05),且观察组低于对照组(P<0.05);两组患者Th1/Th2和Th17/Treg均降低(P<0.05),且观察组低于对照组(P<0.05)。两组患者不良反应总发生率比较无统计学差异(P>0.05)。结论:与单用布地奈德福莫特罗吸入粉雾剂相比,阿托伐他汀钙片联合布地奈德福莫特罗吸入粉雾剂治疗COPD的临床疗效更佳,可有效改善患者肺功能、血气分析指标,且未增加不良反应的发生风险。

复方丹参滴丸联合阿托伐他汀钙治疗慢性心力衰竭临床观察

目的探讨复方丹参滴丸联合阿托伐他汀钙对慢性心力衰竭(congestive heart failure,CHF)患者心功能及细胞因子的影响。方法选取2020年8月—2022年8月就诊于济宁市中医院CHF患者92例进行研究,按照随机数字表法分为2组,各46例。对照组予以阿托伐他汀钙片进行治疗,观察组在对照组基础上采用复方丹参滴丸进行治疗,于治疗3个月后评估。对比2组临床疗效、心功能、细胞因子、血管活性物质、不良反应。结果观察组治疗总有效率(95.65%)高于对照组(80.43%),差异有统计学意义(P<0.05)。治疗前2组心功能、细胞因子、血管活性物质对比,差异无统计学意义(P>0.05);与对照组对比,观察组治疗后左室射血分数(left ventricular ejection fractions,LVEF)高,左室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、左室收缩末期内径(left ventricular end systolic diameter,LVESD)低,6 min步行距离(six minute walk distance,6MWD)长,可溶性生长刺激表达基因2蛋白(soluble growth stimulation expression gene 2 protein,sST2)、半乳糖凝集素-3(galectin-3)水平均低,内皮素-1(endothelin-1,ET-1)、血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、脑利钠肽(brain natriuretic peptide,BNP)水平均低(P<0.05)。观察组不良反应(13.04%)与对照组(10.87%)对比,差异无统计学意义(P>0.05)。结论CHF患者经复方丹参滴丸与阿托伐他汀钙治疗后心功能得到显著改善,且血清细胞因子水平趋于正常,血管活性物质生成有效一致,且安全性高。